Frank Ruffo, Chief Financial Officer at Aclaris Therapeutics, Inc. (ACRS), bought 1,250 shares at $18.22 ($23K) on 2018-05-07, disclosed to the SEC on 2018-05-07.
Scheduled purchase ($23k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ACRS | SELL | 2021-06-02 | $596K | — | Filing → |
| ACRS | SELL | 2021-04-26 | $3.0M | — | Filing → |
| ACRS | BUY | 2018-04-09 | $21K | — | Filing → |